Cardenolide | 52085-71-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Cardenolide
• 英文别名: 3-[(8R,9S,10S,13S,14R,17S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
• CAS: 52085-71-9
• 化学式: C₂₃H₃₄O₂
• 分子量: 342.5
• InChiKey: JIUWTCXNUNHEGP-GJHPUSIBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  25
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Topical and oral formulations of cardiac glycosides for treating skin diseases
  申请人：Streeper Robert

  公开号：US20060205679A1

  公开（公告）日：2006-09-14

  The present invention provides method, preparation and use of a variety of pharmaceutical compositions containing at least one digitalis glycoside such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin alone or at least one digitalis glycoside complexed with cyclodextrins. In another aspect, the present invention provides an effective method to treat diseases in mammals. In yet another aspect, the present invention provides an effective method for treating skin diseases in a human or non-human animal.

  本发明提供了一种方法、制备和使用多种含有至少一种毛地黄苷类药物成分的药物组合物，例如奥利安定、奥多罗苷A、内里福林、普罗斯西拉里丁A、甲基普罗斯西拉里丁A、地高辛、地高辛或至少一种毛地黄苷类与环糊精络合的药物。另一方面，本发明提供了一种有效的方法来治疗哺乳动物的疾病。另一方面，本发明提供了一种有效的方法来治疗人类或非人类动物的皮肤疾病。
• Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
  申请人：Azaya Therapeutics Inc.

  公开号：US20040082521A1

  公开（公告）日：2004-04-29

  The present invention provides methods, preparations, and uses of a variety of liposomal-digitalis glycoside compositions. The present invention also provides protein-stabilized nanoparticle formulations containing liposomal-digitalis glycosides such as Oleandrin, digitoxin, and digoxin with reduced toxicity, high drug to lipid ratio, long circulating time in the bloodstream and the ability to deliver the drug to tumor sites. In another aspect, the present invention provides an effective method to reduce the growth of cancers or reduce the incidence of metastases.

  本发明提供了各种脂质体-地高辛苷组合物的方法、制备和用途。本发明还提供了含有脂质体-地高辛苷（如奥利司琼、地高辛和地高辛）的蛋白质稳定纳米粒子制剂，具有毒性低、药物与脂质比高、在血液中循环时间长以及能将药物输送到肿瘤部位等特点。另一方面，本发明提供了一种减少癌症生长或降低转移发生率的有效方法。
• Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
  申请人：Singh U. Chandra

  公开号：US20050026849A1

  公开（公告）日：2005-02-03

  The present invention provides method, preparation and use of a variety of pharmaceutical composition containing at least one digitalis glycosides such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin and amorphous cyclodextrins. In another aspect, the present invention provides an effective method to reduce the growth of cancers or reducing the incidence of metastases. In yet another aspect, the present invention provides an effective method for treating diseases in a warm-blooded animal.

  本发明提供了含有至少一种洋地黄苷的多种药物组合物的方法、制备和使用，这些洋地黄苷如齐墩果素、臭苷-A、聂立夫林、前胡苷-A、甲基前胡苷-A、地高辛、地高辛和无定形环糊精。另一方面，本发明提供了一种减少癌症生长或降低癌症转移发生率的有效方法。又一方面，本发明提供了一种治疗温血动物疾病的有效方法。
• ANTI-VIRAL TOPICAL GEL FORMULATIONS CONTAINING A DIURETIC SUCH AS FUROSEMIDE AND/OR A CARDIAC GLYCOSIDE SUCH AS DIGOXIN
  申请人：Henderson Morley Plc

  公开号：EP1942908A2

  公开（公告）日：2008-07-16
• COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS
  申请人：Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.

  公开号：EP3393477A1

  公开（公告）日：2018-10-31